In the RE-LY trial, dabigatran was ruled out with persistently high levels of ALT or AST, the presence of hepatitis A, B, or C, anemia (hemoglobin < 10 g/dL), or thrombocytopenia < 100.000/mm3 [26]. This evidence concerns the gene GPT and Thrombocytopenia.